Hitting the bull’s-eye in metastatic cancers—NSAIDs elevate ROS in Mitochondria, inducing malignant cell death

Pharmaceuticals

Volumn 8, Issue 1, 2015, Pages 62-106

  Ralph, Stephen John ^a   Pritchard, Rhys ^a   Rodríguez Enríquez, Sara ^b,c   Moreno Sánchez, Rafael ^b   Ralph, Raymond Keith ^a  

^a GRIFFITH UNIVERSITY   (Australia)

^b INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

^c INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

Author keywords

Cancer cells; Metastasis; Mitochondrial permeability transition pore; Non steroidal anti inflammatory drugs; Reactive oxygen species

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; ATORVASTATIN; CALCIUM CHANNEL; CARBOPLATIN; CELECOXIB; CYSTEINE; DICLOFENAC; DOCETAXEL; FLURBIPROFEN; GLUTAREDOXIN; IBUPROFEN; INDOMETACIN; MITOCHONDRIAL DNA; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; P66SHC PROTEIN; PARACETAMOL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; REACTIVE OXYGEN METABOLITE; REGULATOR PROTEIN; SUCCINIC ACID; SULINDAC; THIOL; THIOREDOXIN; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; BONE METASTASIS; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CELL DEATH; CELL HYPOXIA; CELL MEMBRANE DEPOLARIZATION; CELL SURVIVAL; COLORECTAL CANCER; DOWN REGULATION; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; DRUG TARGETING; HUMAN; METASTASIS; MITOCHONDRIAL PERMEABILITY; MITOCHONDRIAL RESPIRATION; MOLECULAR DYNAMICS; MULTIDRUG RESISTANCE; MUTATION; NONHUMAN; OVARY CANCER; OVARY CARCINOMA; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PHENOTYPE; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN MODIFICATION; REVIEW;

EID: 84922983621     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph8010062     Document Type: Review

References (287)

1. Menzies, A.M.; Long, G.V. Recent advances in melanoma systemic therapy. Braf inhibitors, ctla4 antibodies and beyond. Eur. J. Cancer 2013, 49, 3229-3241.
2. Jackson, S.E.; Chester, J.D. Personalised cancer medicine. Int. J. Cancer 2014. DOI: 10.1002/ijc.28940.
3. Spano, D.; Heck, C.; de Antonellis, P.; Christofori, G.; Zollo, M. Molecular networks that regulate cancer metastasis. Semin. Cancer Biol. 2012, 22, 234-249.
4. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646-674.
5. Harris, A.L. Hypoxia-A key regulatory factor in tumour growth. Nat. Rev. Cancer 2002, 2, 38-47.
6. Semenza, G.L. Hypoxia-inducible factors: Mediators of cancer progression and targets for cancer therapy. Trends Pharmacol. Sci. 2012, 33, 207-214.
7. Ralph, S.J.; Rodriguez-Enriquez, S.; Neuzil, J.; Saavedra, E.; Moreno-Sanchez, R. The causes of cancer revisited: "Mitochondrial malignancy" and ros-induced oncogenic transformation - why mitochondria are targets for cancer therapy. Mol. Asp. Med. 2010, 31, 145-170.
8. Kim, Y.; Lin, Q.; Glazer, P.M.; Yun, Z. Hypoxic tumor microenvironment and cancer cell differentiation. Curr. Mol. Med. 2009, 9, 425-434.
9. Hardee, M.E.; Dewhirst, M.W.; Agarwal, N.; Sorg, B.S. Novel imaging provides new insights into mechanisms of oxygen transport in tumors. Curr. Mol. Med. 2009, 9, 435-441.
10. Majmundar, A.J.; Wong, W.J.; Simon, M.C. Hypoxia-inducible factors and the response to hypoxic stress. Mol. Cell 2010, 40, 294-309.
11. Kingsley, L.A.; Fournier, P.G.; Chirgwin, J.M.; Guise, T.A. Molecular biology of bone metastasis. Mol. Cancer Ther. 2007, 6, 2609-2617.
12. Hirayama, A.; Kami, K.; Sugimoto, M.; Sugawara, M.; Toki, N.; Onozuka, H.; Kinoshita, T.; Saito, N.; Ochiai, A.; Tomita, M.; et al. Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry. Cancer Res. 2009, 69, 4918-4925.
13. Keith, B.; Simon, M.C. Hypoxia-inducible factors, stem cells, and cancer. Cell 2007, 129, 465-472.
14. Heddleston, J.M.; Li, Z.; Lathia, J.D.; Bao, S.; Hjelmeland, A.B.; Rich, J.N. Hypoxia inducible factors in cancer stem cells. Br. J. Cancer 2010, 102, 789-795.
15. Liang, D.; Ma, Y.; Liu, J.; Trope, C.G.; Holm, R.; Nesland, J.M.; Suo, Z. The hypoxic microenvironment upgrades stem-like properties of ovarian cancer cells. BMC Cancer 2012, 12, 201.
16. Mathieu, J.; Zhang, Z.; Zhou, W.; Wang, A.J.; Heddleston, J.M.; Pinna, C.M.; Hubaud, A.; Stadler, B.; Choi, M.; Bar, M.; et al. Hif induces human embryonic stem cell markers in cancer cells. Cancer Res. 2011, 71, 4640-4652.
17. Li, Z.; Rich, J.N. Hypoxia and hypoxia inducible factors in cancer stem cell maintenance. Curr. Top. Microbiol. Immunol. 2010, 345, 21-30.
18. Fabian, A.; Vereb, G.; Szollosi, J. The hitchhikers guide to cancer stem cell theory: Markers, pathways and therapy. Cytom. Part A J. Int. Soc. Anal. Cytol. 2013, 83, 62-71.
19. Sun, Y.; Chen, J.; Rigas, B. Chemopreventive agents induce oxidative stress in cancer cells leading to cox-2 overexpression and cox-2-independent cell death. Carcinogenesis 2009, 30, 93-100.
20. Warburg, O. On respiratory impairment in cancer cells. Science 1956, 124, 269-270.
21. Warburg, O. On the origin of cancer cells. Science 1956, 123, 309-314.
22. Ralph, S.J.; Rodriguez-Enriquez, S.; Neuzil, J.; Moreno-Sanchez, R. Bioenergetic pathways in tumor mitochondria as targets for cancer therapy and the importance of the ros-induced apoptotic trigger. Mol. Asp. Med. 2010, 31, 29-59.
23. Rodriguez-Enriquez, S.; Gallardo-Perez, J.C.; Marin-Hernandez, A.; Aguilar-Ponce, J.L.; Mandujano-Tinoco, E.A.; Meneses, A.; Moreno-Sanchez, R. Oxidative phosphorylation as a target to arrest malignant neoplasias. Curr. Med. Chem. 2011, 18, 3156-3167.
24. Moreno-Sanchez, R.; Marin-Hernandez, A.; Saavedra, E.; Pardo, J.P.; Ralph, S.J.; Rodriguez-Enriquez, S. Who controls the atp supply in cancer cells? Biochemistry lessons to understand cancer energy metabolism. Int. J. Biochem. Cell Biol. 2014, 50, 10-23.
25. Fan, J.; Kamphorst, J.J.; Mathew, R.; Chung, M.K.; White, E.; Shlomi, T.; Rabinowitz, J.D. Glutamine-driven oxidative phosphorylation is a major atp source in transformed mammalian cells in both normoxia and hypoxia. Mol. Syst. Biol. 2013, 9, 712.
26. Bensaad, K.; Harris, A.L. Hypoxia and metabolism in cancer. Adv. Exp. Med. Biol. 2014, 772, 1-39.
27. Neuzil, J.; Dong, L.F.; Rohlena, J.; Truksa, J.; Ralph, S.J. Classification of mitocans, anti-cancer drugs acting on mitochondria. Mitochondrion 2013, 13, 199-208.
28. Fulda, S. Exploiting mitochondrial apoptosis for the treatment of cancer. Mitochondrion 2010, 10, 598-603.
29. Li, X.; Fang, P.; Mai, J.; Choi, E.T.; Wang, H.; Yang, X.F. Targeting mitochondrial reactive oxygen species as novel therapy for inflammatory diseases and cancers. J. Hematol. Oncol. 2013, 6, 19.
30. Pollak, M. Targeting oxidative phosphorylation: Why, when, and how. Cancer Cell 2013, 23, 263-264.
31. Glasauer, A.; Chandel, N.S. Targeting antioxidants for cancer therapy. Biochem. Pharmacol. 2014, 92, 90-101.
32. Heerdt, B.G.; Houston, M.A.; Augenlicht, L.H. The intrinsic mitochondrial membrane potential of colonic carcinoma cells is linked to the probability of tumor progression. Cancer Res. 2005, 65, 9861-9867.
33. Houston, M.A.; Augenlicht, L.H.; Heerdt, B.G. Stable differences in intrinsic mitochondrial membrane potential of tumor cell subpopulations reflect phenotypic heterogeneity. Int. J. Cell Biol. 2011, 2011, 978583.
34. Bonuccelli, G.; Tsirigos, A.; Whitaker-Menezes, D.; Pavlides, S.; Pestell, R.G.; Chiavarina, B.; Frank, P.G.; Flomenberg, N.; Howell, A.; Martinez-Outschoorn, U.E.; et al. Ketones and lactate "fuel" tumor growth and metastasis: Evidence that epithelial cancer cells use oxidative mitochondrial metabolism. Cell Cycle 2010, 9, 3506-3514.
35. Whitaker-Menezes, D.; Martinez-Outschoorn, U.E.; Flomenberg, N.; Birbe, R.C.; Witkiewicz, A.K.; Howell, A.; Pavlides, S.; Tsirigos, A.; Ertel, A.; Pestell, R.G.; et al. Hyperactivation of oxidative mitochondrial metabolism in epithelial cancer cells in situ: Visualizing the therapeutic effects of metformin in tumor tissue. Cell Cycle 2011, 10, 4047-4064.
36. Sotgia, F.; Whitaker-Menezes, D.; Martinez-Outschoorn, U.E.; Flomenberg, N.; Birbe, R.C.; Witkiewicz, A.K.; Howell, A.; Philp, N.J.; Pestell, R.G.; Lisanti, M.P. Mitochondrial metabolism in cancer metastasis: Visualizing tumor cell mitochondria and the "reverse warburg effect" in positive lymph node tissue. Cell Cycle 2012, 11, 1445-1454.
37. Sotgia, F.; Martinez-Outschoorn, U.E.; Lisanti, M.P. Mitochondrial oxidative stress drives tumor progression and metastasis: Should we use antioxidants as a key component of cancer treatment and prevention? BMC Med. 2011, 9, 62.
38. Vazquez, F.; Lim, J.H.; Chim, H.; Bhalla, K.; Girnun, G.; Pierce, K.; Clish, C.B.; Granter, S.R.; Widlund, H.R.; Spiegelman, B.M.; et al. Pgc1alpha expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress. Cancer Cell 2013, 23, 287-301.
39. LeBleu, V.S.; O'Connell, J.T.; Gonzalez Herrera, K.N.; Wikman, H.; Pantel, K.; Haigis, M.C.; de Carvalho, F.M.; Damascena, A.; Domingos Chinen, L.T.; Rocha, R.M.; et al. Pgc-1alpha mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. Nat. Cell Biol. 2014, 16, 992-1003.
40. Kong, X.; Wang, R.; Xue, Y.; Liu, X.; Zhang, H.; Chen, Y.; Fang, F.; Chang, Y. Sirtuin 3, a new target of pgc-1alpha, plays an important role in the suppression of ROS and mitochondrial biogenesis. PLoS One 2010, 5, e11707.
41. Giralt, A.; Hondares, E.; Villena, J.A.; Ribas, F.; Diaz-Delfin, J.; Giralt, M.; Iglesias, R.; Villarroya, F. Peroxisome proliferator-activated receptor-gamma coactivator-1alpha controls transcription of the sirt3 gene, an essential component of the thermogenic brown adipocyte phenotype. J. Biol. Chem. 2011, 286, 16958-16966.
42. Deblois, G.; St-Pierre, J.; Giguere, V. The pgc-1/err signaling axis in cancer. Oncogene 2013, 32, 3483-3490.
43. Zorov, D.B.; Juhaszova, M.; Sollott, S.J. Mitochondrial reactive oxygen species (ros) and rosinduced ROS release. Physiol. Rev. 2014, 94, 909-950.
44. Hoffman, D.L.; Brookes, P.S. Oxygen sensitivity of mitochondrial reactive oxygen species generation depends on metabolic conditions. J. Biol. Chem. 2009, 284, 16236-16245.
45. Jackson, R.M.; Parish, G.; Ho, Y.S. Effects of hypoxia on expression of superoxide dismutases in cultured atii cells and lung fibroblasts. Am. J. Physiol. 1996, 271, L955-962.
46. Fan, J.; Cai, H.; Yang, S.; Yan, L.; Tan, W. Comparison between the effects of normoxia and hypoxia on antioxidant enzymes and glutathione redox state in ex vivo culture of cd34(+) cells. Comp. Biochem. Physiol. Part B Biochem. Mol. Biol. 2008, 151, 153-158.
47. Xi, H.; Gao, Y.H.; Han, D.Y.; Li, Q.Y.; Feng, L.J.; Zhang, W.; Ji, G.; Xiao, J.C.; Zhang, H.Z.; Wei, Q. Hypoxia inducible factor-1alpha suppresses peroxiredoxin 3 expression to promote proliferation of ccrcc cells. FEBS Lett. 2014, 588, 3390-3394.
48. Hsieh, C.H.; Wu, C.P.; Lee, H.T.; Liang, J.A.; Yu, C.Y.; Lin, Y.J. Nadph oxidase subunit 4 mediates cycling hypoxia-promoted radiation resistance in glioblastoma multiforme. Free Radic. Biol. Med. 2012, 53, 649-658.
49. Scannell, G.; Waxman, K.; Kaml, G.J.; Ioli, G.; Gatanaga, T.; Yamamoto, R.; Granger, G.A. Hypoxia induces a human macrophage cell line to release tumor necrosis factor-alpha and its soluble receptors in vitro. J. Surg. Res. 1993, 54, 281-285.
50. Moreno-Sanchez, R.; Hernandez-Esquivel, L.; Rivero-Segura, N.A.; Marin-Hernandez, A.; Neuzil, J.; Ralph, S.J.; Rodriguez-Enriquez, S. Reactive oxygen species are generated by the respiratory complex ii-Evidence for lack of contribution of the reverse electron flow in complex i. FEBS J. 2013, 280, 927-938.
51. Chen, Y.R.; Zweier, J.L. Cardiac mitochondria and reactive oxygen species generation. Circ. Res. 2014, 114, 524-537.
52. Korshunov, S.S.; Skulachev, V.P.; Starkov, A.A. High protonic potential actuates a mechanism of production of reactive oxygen species in mitochondria. FEBS Lett. 1997, 416, 15-18.
53. Chouchani, E.T., Pell, V.R., Gaude, E., Aksentijevic, D. Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS. Nature 2014, 515, 431-435.
54. Zhang, L.; Yu, L.; Yu, C.A. Generation of superoxide anion by succinate-cytochrome c reductase from bovine heart mitochondria. J. Biol. Chem. 1998, 273, 33972-33976.
55. Rottenberg, H.; Covian, R.; Trumpower, B.L. Membrane potential greatly enhances superoxide generation by the cytochrome bc1 complex reconstituted into phospholipid vesicles. J. Biol. Chem. 2009, 284, 19203-19210.
56. Wallace, D.C. A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: A dawn for evolutionary medicine. Annu. Rev. Genet. 2005, 39, 359-407.
57. Turrens, J.F. Superoxide production by the mitochondrial respiratory chain. Biosci. Rep. 1997, 17, 3-8.
58. McLennan, H.R.; Degli Esposti, M. The contribution of mitochondrial respiratory complexes to the production of reactive oxygen species. J. Bioenerg. Biomembr. 2000, 32, 153-162.
59. Lenaz, G.; D'Aurelio, M.; Merlo Pich, M.; Genova, M.L.; Ventura, B.; Bovina, C.; Formiggini, G.; Parenti Castelli, G. Mitochondrial bioenergetics in aging. Biochim. Biophys. Acta 2000, 1459, 397-404.
60. Paddenberg, R.; Ishaq, B.; Goldenberg, A.; Faulhammer, P.; Rose, F.; Weissmann, N.; Braun-Dullaeus, R.C.; Kummer, W. Essential role of complex ii of the respiratory chain in hypoxia-induced ROS generation in the pulmonary vasculature. Am. J. Physiol. Lung Cell. Mol. Physiol. 2003, 284, L710-L719.
61. Zuckerbraun, B.S.; Chin, B.Y.; Bilban, M.; d'Avila, J.C.; Rao, J.; Billiar, T.R.; Otterbein, L.E. Carbon monoxide signals via inhibition of cytochrome c oxidase and generation of mitochondrial reactive oxygen species. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 2007, 21, 1099-1106.
62. Brookes, P.S. Mitochondrial h(+) leak and ROS generation: An odd couple. Free Radic. Biol. Med. 2005, 38, 12-23.
63. Cortassa, S.; O'Rourke, B.; Aon, M.A. Redox-optimized ROS balance and the relationship between mitochondrial respiration and ros. Biochim. Biophys. Acta 2014, 1837, 287-295.
64. Tretter, L.; Biagioni Angeli, E.; Ardestani, M.R.; Goracci, G.; Adam-Vizi, V. Reversible inhibition of hydrogen peroxide elimination by calcium in brain mitochondria. J. Neurosci. Res. 2011, 89, 1965-1972.
65. Montero, J.; Mari, M.; Colell, A.; Morales, A.; Basanez, G.; Garcia-Ruiz, C.; Fernandez-Checa, J.C. Cholesterol and peroxidized cardiolipin in mitochondrial membrane properties, permeabilization and cell death. Biochim. Biophys. Acta 2010, 1797, 1217-1224.
66. Turrens, J.F.; Alexandre, A.; Lehninger, A.L. Ubisemiquinone is the electron donor for superoxide formation by complex iii of heart mitochondria. Arch. Biochem. Biophys. 1985, 237, 408-414.
67. Paranagama, M.P.; Sakamoto, K.; Amino, H.; Awano, M.; Miyoshi, H.; Kita, K. Contribution of the fad and quinone binding sites to the production of reactive oxygen species from ascaris suum mitochondrial complex ii. Mitochondrion 2010, 10, 158-165.
68. Drose, S.; Brandt, U. Molecular mechanisms of superoxide production by the mitochondrial respiratory chain. Adv. Exp. Med. Biol. 2012, 748, 145-169.
69. Watson, J. Oxidants, antioxidants and the current incurability of metastatic cancers. Open Biol. 2013, 3, 120144.
70. He, X.; Zhou, A.; Lu, H.; Chen, Y.; Huang, G.; Yue, X.; Zhao, P.; Wu, Y. Suppression of mitochondrial complex i influences cell metastatic properties. PLoS One 2013, 8, e61677.
71. Porporato, P.E.; Payen, V.L.; Perez-Escuredo, J.; de Saedeleer, C.J.; Danhier, P.; Copetti, T.; Dhup, S.; Tardy, M.; Vazeille, T.; Bouzin, C.; et al. A mitochondrial switch promotes tumor metastasis. Cell Rep. 2014, 8, 754-766.
72. Nishikawa, M. Reactive oxygen species in tumor metastasis. Cancer Lett. 2008, 266, 53-59.
73. Ishikawa, K.; Takenaga, K.; Akimoto, M.; Koshikawa, N.; Yamaguchi, A.; Imanishi, H.; Nakada, K.; Honma, Y.; Hayashi, J. Ros-generating mitochondrial DNA mutations can regulate tumor cell metastasis. Science 2008, 320, 661-664.
74. Ishikawa, K.; Hayashi, J. A novel function of mtdna: Its involvement in metastasis. Ann. N. Y. Acad. Sci. 2010, 1201, 40-43.
75. Tamura, M.; Matsui, H.; Tomita, T.; Sadakata, H.; Indo, H.P.; Majima, H.J.; Kaneko, T.; Hyodo, I. Mitochondrial reactive oxygen species accelerate gastric cancer cell invasion. J. Clin. Biochem. Nutr. 2014, 54, 12-17.
76. Yao, Z.; Jones, A.W.; Fassone, E.; Sweeney, M.G.; Lebiedzinska, M.; Suski, J.M.; Wieckowski, M.R.; Tajeddine, N.; Hargreaves, I.P.; Yasukawa, T.; et al. Pgc-1beta mediates adaptive chemoresistance associated with mitochondrial DNA mutations. Oncogene 2013, 32, 2592-2600.
77. O'Hagan, K.A.; Cocchiglia, S.; Zhdanov, A.V.; Tambuwala, M.M.; Cummins, E.P.; Monfared, M.; Agbor, T.A.; Garvey, J.F.; Papkovsky, D.B.; Taylor, C.T.; et al. Pgc-1alpha is coupled to hif-1alpha-dependent gene expression by increasing mitochondrial oxygen consumption in skeletal muscle cells. Proc. Natl. Acad. Sci. USA 2009, 106, 2188-2193.
78. Comerford, K.M.; Wallace, T.J.; Karhausen, J.; Louis, N.A.; Montalto, M.C.; Colgan, S.P. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (mdr1) gene. Cancer Res. 2002, 62, 3387-3394.
79. Xia, S.; Yu, S.Y.; Yuan, X.L.; Xu, S.P. Effects of hypoxia on expression of p-glycoprotein and multidrug resistance protein in human lung adenocarcinoma a549 cell line. Zhonghua yi xue za zhi 2004, 84, 663-666.
80. Milane, L.; Duan, Z.; Amiji, M. Role of hypoxia and glycolysis in the development of multi-drug resistance in human tumor cells and the establishment of an orthotopic multi-drug resistant tumor model in nude mice using hypoxic pre-conditioning. Cancer Cell Int. 2011, 11, 3.
81. Min, L.; Chen, Q.; He, S.; Liu, S.; Ma, Y. Hypoxia-induced increases in a549/cddp cell drug resistance are reversed by rna interference of hif-1alpha expression. Mol. Med. Rep. 2012, 5, 228-232.
82. Zhan, M.; Yu, D.; Lang, A.; Li, L.; Pollock, R.E. Wild type p53 sensitizes soft tissue sarcoma cells to doxorubicin by down-regulating multidrug resistance-1 expression. Cancer 2001, 92, 1556-1566.
83. De Rosa, M.F.; Sillence, D.; Ackerley, C.; Lingwood, C. Role of multiple drug resistance protein 1 in neutral but not acidic glycosphingolipid biosynthesis. J. Biol. Chem. 2004, 279, 7867-7876.
84. Baran, Y.; Gunduz, U.; Ural, A.U. Expression of multidrug resistance (mdr-1) gene in human promyelocytic leukemia cell line selected with vincristine. Turk. J. Cancer 2005, 35, 88-92.
85. Loe, D.W.; Deeley, R.G.; Cole, S.P. Biology of the multidrug resistance-associated protein, mrp. Eur. J. Cancer 1996, 32A, 945-957.
86. Green, D.R.; Galluzzi, L.; Kroemer, G. Cell biology. Metabolic control of cell death. Science 2014, 345, 1250256.
87. Kruspig, B.; Zhivotovsky, B.; Gogvadze, V. Mitochondrial substrates in cancer: Drivers or passengers? Mitochondrion 2014, 19, 8-19.
88. Ralph, S.J.; Neuzil, J. Mitochondria as targets for cancer therapy. Mol. Nutr. Food Res. 2009, 53, 9-28.
89. Ralph, S.J.; Low, P.; Dong, L.; Lawen, A.; Neuzil, J. Mitocans: Mitochondrial targeted anti-cancer drugs as improved therapies and related patent documents. Recent Pat. Anti-Cancer Drug Discov. 2006, 1, 327-346.
90. Neuzil, J.; Dyason, J.C.; Freeman, R.; Dong, L.F.; Prochazka, L.; Wang, X.F.; Scheffler, I.; Ralph, S.J. Mitocans as anti-cancer agents targeting mitochondria: Lessons from studies with vitamin e analogues, inhibitors of complex ii. J. Bioenerg. Biomembr. 2007, 39, 65-72.
91. Neuzil, J.; Wang, X.F.; Dong, L.F.; Low, P.; Ralph, S.J. Molecular mechanism of 'mitocan'- induced apoptosis in cancer cells epitomizes the multiple roles of reactive oxygen species and bcl-2 family proteins. FEBS Lett. 2006, 580, 5125-5129.
92. Makris, U.E.; Abrams, R.C.; Gurland, B.; Reid, M.C. Management of persistent pain in the older patient: A clinical review. JAMA 2014, 312, 825-836.
93. McCarberg, B.H.; Cryer, B. Evolving therapeutic strategies to improve nonsteroidal antiinflammatory drug safety. Am. J. Ther. 2014. doi: 10.1097/MJT.0000000000000123.
94. Wehling, M. Non-steroidal anti-inflammatory drug use in chronic pain conditions with special emphasis on the elderly and patients with relevant comorbidities: Management and mitigation of risks and adverse effects. Eur. J. Clin. Pharmacol. 2014, 70, 1159-1172.
95. Unzueta, A.; Vargas, H.E. Nonsteroidal anti-inflammatory drug-induced hepatoxicity. Clin. Liver Dis. 2013, 17, 643-656.
96. Sostres, C.; Gargallo, C.J.; Lanas, A. Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage. Arthritis Res. Ther. 2013, 15 (Suppl 3), S3.
97. Nadanaciva, S.; Aleo, M.D.; Strock, C.J.; Stedman, D.B.; Wang, H.; Will, Y. Toxicity assessments of nonsteroidal anti-inflammatory drugs in isolated mitochondria, rat hepatocytes, and zebrafish show good concordance across chemical classes. Toxicol. Appl. Pharmacol. 2013, 272, 272-280.
98. Trabert, B.; Ness, R.B.; Lo-Ciganic, W.H.; Murphy, M.A.; Goode, E.L.; Poole, E.M.; Brinton, L.A.; Webb, P.M.; Nagle, C.M.; Jordan, S.J.; et al. Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: A pooled analysis in the ovarian cancer association consortium. J. Natl. Cancer Inst. 2014, 106, djt431.
99. Gurpinar, E.; Grizzle, W.E.; Piazza, G.A. NSAIDs inhibit tumorigenesis, but how? Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2014, 20, 1104-1113.
100. Cuzick, J.; Thorat, M.A.; Andriole, G.; Brawley, O.W.; Brown, P.H.; Culig, Z.; Eeles, R.A.; Ford, L.G.; Hamdy, F.C.; Holmberg, L.; et al. Prevention and early detection of prostate cancer. Lancet. Oncol. 2014, 15, e484-e492.
101. Cooper, K.; Squires, H.; Carroll, C.; Papaioannou, D.; Booth, A.; Logan, R.F.; Maguire, C.; Hind, D.; Tappenden, P. Chemoprevention of colorectal cancer: Systematic review and economic evaluation. Health Technol. Assess. 2010, 14, 1-206.
102. Guadagni, F.; Ferroni, P.; Palmirotta, R.; Del Monte, G.; Formica, V.; Roselli, M. Non-steroidal anti-inflammatory drugs in cancer prevention and therapy. Anticancer Res. 2007, 27, 3147-3162.
103. Liggett, J.L.; Zhang, X.; Eling, T.E.; Baek, S.J. Anti-tumor activity of non-steroidal antiinflammatory drugs: Cyclooxygenase-independent targets. Cancer Lett. 2014, 346, 217-224.
104. Waskewich, C.; Blumenthal, R.D.; Li, H.; Stein, R.; Goldenberg, D.M.; Burton, J. Celecoxib exhibits the greatest potency amongst cyclooxygenase (cox) inhibitors for growth inhibition of cox-2-negative hematopoietic and epithelial cell lines. Cancer Res. 2002, 62, 2029-2033.
105. Song, X.; Lin, H.P.; Johnson, A.J.; Tseng, P.H.; Yang, Y.T.; Kulp, S.K.; Chen, C.S. Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. J. Natl. Cancer Inst. 2002, 94, 585-591.
106. Shao, D.; Kan, M.; Qiao, P.; Pan, Y.; Wang, Z.; Xiao, X.; Li, J.; Chen, L. Celecoxib induces apoptosis via a mitochondriadependent pathway in the h22 mouse hepatoma cell line. Mol. Med. Rep. 2014, 10, 2093-2098.
107. Hashitani, S.; Urade, M.; Nishimura, N.; Maeda, T.; Takaoka, K.; Noguchi, K.; Sakurai, K. Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines. Int. J. Oncol. 2003, 23, 665-672.
108. Duncan, K.; Uwimpuhwe, H.; Czibere, A.; Sarkar, D.; Libermann, T.A.; Fisher, P.B.; Zerbini, L.F. NSAIDs induce apoptosis in nonproliferating ovarian cancer cells and inhibit tumor growth in vivo. IUBMB Life 2012, 64, 636-643.
109. Kim, H.J.; Yim, G.W.; Nam, E.J.; Kim, Y.T. Synergistic effect of cox-2 inhibitor on paclitaxelinduced apoptosis in the human ovarian cancer cell line ovcar-3. Cancer Res. Treat. Off. J. Korean Cancer Assoc. 2014, 46, 81-92.
110. Moreno-Sanchez, R.; Rodriguez-Enriquez, S.; Marin-Hernandez, A.; Saavedra, E. Energy metabolism in tumor cells. FEBS J. 2007, 274, 1393-1418.
111. Farrugia, G.; Balzan, R. The proapoptotic effect of traditional and novel nonsteroidal anti-inflammatory drugs in mammalian and yeast cells. Oxidative Med. Cell. Longev. 2013, 2013, 504230.
112. Khwaja, F.; Allen, J.; Lynch, J.; Andrews, P.; Djakiew, D. Ibuprofen inhibits survival of bladder cancer cells by induced expression of the p75ntr tumor suppressor protein. Cancer Res. 2004, 64, 6207-6213.
113. Andrews, J.; Djakiew, D.; Krygier, S.; Andrews, P. Superior effectiveness of ibuprofen compared with other NSAIDs for reducing the survival of human prostate cancer cells. Cancer Chemother. Pharmacol. 2002, 50, 277-284.
114. Andrews, P.; Zhao, X.; Allen, J.; Li, F.; Chang, M. A comparison of the effectiveness of selected non-steroidal anti-inflammatory drugs and their derivatives against cancer cells in vitro. Cancer Chemother. Pharmacol. 2008, 61, 203-214.
115. Narayanan, B.A.; Narayanan, N.K.; Pittman, B.; Reddy, B.S. Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2004, 10, 7727-7737.
116. Ishiguro, H.; Kawahara, T. Nonsteroidal anti-inflammatory drugs and prostatic diseases. BioMed Res. Int. 2014, 2014, 436123.
117. Pathi, S.; Jutooru, I.; Chadalapaka, G.; Nair, V.; Lee, S.O.; Safe, S. Aspirin inhibits colon cancer cell and tumor growth and downregulates specificity protein (sp) transcription factors. PLoS One 2012, 7, e48208.
118. Valle, B.L.; D'Souza, T.; Becker, K.G.; Wood, W.H., 3rd; Zhang, Y.; Wersto, R.P.; Morin, P.J. Non-steroidal anti-inflammatory drugs decrease e2f1 expression and inhibit cell growth in ovarian cancer cells. PLoS One 2013, 8, e61836.
119. Goluboff, E.T.; Shabsigh, A.; Saidi, J.A.; Weinstein, I.B.; Mitra, N.; Heitjan, D.; Piazza, G.A.; Pamukcu, R.; Buttyan, R.; Olsson, C.A. Exisulind (sulindac sulfone) suppresses growth of human prostate cancer in a nude mouse xenograft model by increasing apoptosis. Urology 1999, 53, 440-445.
120. Zheng, X.; Cui, X.X.; Avila, G.E.; Huang, M.T.; Liu, Y.; Patel, J.; Kong, A.N.; Paulino, R.; Shih, W.J.; Lin, Y.; et al. Atorvastatin and celecoxib inhibit prostate pc-3 tumors in immunodeficient mice. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2007, 13, 5480-5487.
121. Zheng, X.; Cui, X.X.; Gao, Z.; Zhao, Y.; Lin, Y.; Shih, W.J.; Huang, M.T.; Liu, Y.; Rabson, A.; Reddy, B.; et al. Atorvastatin and celecoxib in combination inhibits the progression of androgen-dependent lncap xenograft prostate tumors to androgen independence. Cancer Prev. Res. 2010, 3, 114-124.
122. Wang, H.; Cui, X.X.; Goodin, S.; Ding, N.; van Doren, J.; Du, Z.; Huang, M.T.; Liu, Y.; Cheng, X.; Dipaola, R.S.; et al. Inhibition of il-6 expression in lncap prostate cancer cells by a combination of atorvastatin and celecoxib. Oncol. Rep. 2014, 31, 835-841.
123. Huang, H.; Cui, X.X.; Chen, S.; Goodin, S.; Liu, Y.; He, Y.; Li, D.; Wang, H.; van Doren, J.; Dipaola, R.S.; et al. Combination of lipitor and celebrex inhibits prostate cancer vcap cells in vitro and in vivo. Anticancer Res. 2014, 34, 3357-3363.
124. Lonnroth, C.; Andersson, M.; Asting, A.G.; Nordgren, S.; Lundholm, K. Preoperative low dose nsaid treatment influences the genes for stemness, growth, invasion and metastasis in colorectal cancer. Int. J. Oncol. 2014, 45, 2208-2220.
125. Baggott, J.E.; Morgan, S.L.; Ha, T.; Vaughn, W.H.; Hine, R.J. Inhibition of folate-dependent enzymes by non-steroidal anti-inflammatory drugs. Biochem. J. 1992, 282 (Pt 1), 197-202.
126. Reti, A.; Pap, E.; Adleff, V.; Jeney, A.; Kralovanszky, J.; Budai, B. Enhanced 5-fluorouracil cytotoxicity in high cyclooxygenase-2 expressing colorectal cancer cells and xenografts induced by non-steroidal anti-inflammatory drugs via downregulation of dihydropyrimidine dehydrogenase. Cancer Chemother. Pharmacol. 2010, 66, 219-227.
127. Reti, A.; Pap, E.; Zalatnai, A.; Jeney, A.; Kralovanszky, J.; Budai, B. Co-inhibition of cyclooxygenase-2 and dihydropyrimidine dehydrogenase by non-steroidal anti-inflammatory drugs in tumor cells and xenografts. Anticancer Res. 2009, 29, 3095-3101.
128. Reti, A.; Barna, G.; Pap, E.; Adleff, V.; Komlósi, V.; Jeney, A.; Kralovanszky, J.; Budai, B. Enhancement of 5-fluorouracil efficacy on high cox-2 expressing hca-7 cells by low dose indomethacin and ns-398 but not on low cox-2 expressing ht-29 cells. Pathol. Oncol. Res. POR 2009, 15, 335-344.
129. Mingatto, F.E.; Santos, A.C.; Uyemura, S.A.; Jordani, M.C.; Curti, C. In vitro interaction of nonsteroidal anti-inflammatory drugs on oxidative phosphorylation of rat kidney mitochondria: Respiration and atp synthesis. Arch. Biochem. Biophys. 1996, 334, 303-308.
130. Moreno-Sanchez, R.; Bravo, C.; Vasquez, C.; Ayala, G.; Silveira, L.H.; Martinez-Lavin, M. Inhibition and uncoupling of oxidative phosphorylation by nonsteroidal anti-inflammatory drugs: Study in mitochondria, submitochondrial particles, cells, and whole heart. Biochem. Pharmacol. 1999, 57, 743-752.
131. Somasundaram, S.; Rafi, S.; Hayllar, J.; Sigthorsson, G.; Jacob, M.; Price, A.B.; Macpherson, A.; Mahmod, T.; Scott, D.; Wrigglesworth, J.M.; et al. Mitochondrial damage: A possible mechanism of the "topical" phase of nsaid induced injury to the rat intestine. Gut 1997, 41, 344-353.
132. Jorgensen, T.G.; Weis-Fogh, U.S.; Nielsen, H.H.; Olesen, H.P. Salicylate- and aspirin-induced uncoupling of oxidative phosphorylation in mitochondria isolated from the mucosal membrane of the stomach. Scand. J. Clin. Lab. Investig. 1976, 36, 649-654.
133. Petrescu, I.; Tarba, C. Uncoupling effects of diclofenac and aspirin in the perfused liver and isolated hepatic mitochondria of rat. Biochim. Biophys. Acta 1997, 1318, 385-394.
134. Battaglia, V.; Salvi, M.; Toninello, A. Oxidative stress is responsible for mitochondrial permeability transition induction by salicylate in liver mitochondria. J. Biol. Chem. 2005, 280, 33864-33872.
135. Pigoso, A.A.; Uyemura, S.A.; Santos, A.C.; Rodrigues, T.; Mingatto, F.E.; Curti, C. Influence of nonsteroidal anti-inflammatory drugs on calcium efflux in isolated rat renal cortex mitochondria and aspects of the mechanisms involved. Int. J. Biochem. Cell Biol. 1998, 30, 961-965.
136. Uyemura, S.A.; Santos, A.C.; Mingatto, F.E.; Jordani, M.C.; Curti, C. Diclofenac sodium and mefenamic acid: Potent inducers of the membrane permeability transition in renal cortex mitochondria. Arch. Biochem. Biophys. 1997, 342, 231-235.
137. Daouphars, M.; Koufany, M.; Benani, A.; Marchal, S.; Merlin, J.L.; Netter, P.; Jouzeau, J.Y. Uncoupling of oxidative phosphorylation and smac/diablo release are not sufficient to account for induction of apoptosis by sulindac sulfide in human colorectal cancer cells. Int. J. Oncol. 2005, 26, 1069-1077.
138. Tomellini, E.; Touil, Y.; Lagadec, C.; Julien, S.; Ostyn, P.; Ziental-Gelus, N.; Meignan, S.; Lengrand, J.; Adriaenssens, E.; Polakowska, R.; et al. NGF and proNGF simultaneously promote symmetric self-renewal, quiescence and emt to enlarge the breast cancer stem cell compartment. Stem Cells 2014, 33, 342-353.
139. Tomellini, E.; Lagadec, C.; Polakowska, R.; le Bourhis, X. Role of p75 neurotrophin receptor in stem cell biology: More than just a marker. Cell. Mol. Life Sci.: CMLS 2014, 71, 2467-2481.
140. Wynne, S.; Djakiew, D. Nsaid inhibition of prostate cancer cell migration is mediated by nag-1 induction via the p38 mapk-p75(ntr) pathway. Mol. Cancer Res.: MCR 2010, 8, 1656-1664.
141. Yang, M.H.; Kim, J.; Khan, I.A.; Walker, L.A.; Khan, S.I. Nonsteroidal anti-inflammatory drug activated gene-1 (nag-1) modulators from natural products as anti-cancer agents. Life Sci. 2014, 100, 75-84.
142. Wang, X.; Chrysovergis, K.; Kosak, J.; Kissling, G.; Streicker, M.; Moser, G.; Li, R.; Eling, T.E. Hnag-1 increases lifespan by regulating energy metabolism and insulin/IGF-1/mTOR signaling. Aging 2014, 6, 690-704.
143. Chrysovergis, K.; Wang, X.; Kosak, J.; Lee, S.H.; Kim, J.S.; Foley, J.F.; Travlos, G.; Singh, S.; Baek, S.J.; Eling, T.E. Nag-1/GDF-15 prevents obesity by increasing thermogenesis, lipolysis and oxidative metabolism. Int. J. Obes. 2014, 38, 1555-1564.
144. Vaish, V.; Piplani, H.; Rana, C.; Vaiphei, K.; Sanyal, S.N. NSAIDs may regulate egr-1-mediated induction of reactive oxygen species and non-steroidal anti-inflammatory drug-induced gene (nag)-1 to initiate intrinsic pathway of apoptosis for the chemoprevention of colorectal cancer. Mol. Cell. Biochem. 2013, 378, 47-64.
145. Legge, F.; Paglia, A.; D'Asta, M.; Fuoco, G.; Scambia, G.; Ferrandina, G. Phase ii study of the combination carboplatin plus celecoxib in heavily pre-treated recurrent ovarian cancer patients. BMC Cancer 2011, 11, 214.
146. Reyners, A.K.; de Munck, L.; Erdkamp, F.L.; Smit, W.M.; Hoekman, K.; Lalisang, R.I.; de Graaf, H.; Wymenga, A.N.; Polee, M.; Hollema, H.; et al. A randomized phase ii study investigating the addition of the specific cox-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage ic to iv epithelial ovarian cancer, fallopian tube or primary peritoneal carcinomas: The docacel study. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol./ESMO 2012, 23, 2896-2902.
147. Chung, Y.M.; Bae, Y.S.; Lee, S.Y. Molecular ordering of ROS production, mitochondrial changes, and caspase activation during sodium salicylate-induced apoptosis. Free Radic. Biol. Med. 2003, 34, 434-442.
148. Sun, Y.; Huang, L.; Mackenzie, G.G.; Rigas, B. Oxidative stress mediates through apoptosis the anticancer effect of phospho-nonsteroidal anti-inflammatory drugs: Implications for the role of oxidative stress in the action of anticancer agents. J. Pharmacol. Exp. Ther. 2011, 338, 775-783.
149. Rigas, B.; Sun, Y. Induction of oxidative stress as a mechanism of action of chemopreventive agents against cancer. Br. J. Cancer 2008, 98, 1157-1160.
150. Gao, J.; Niwa, K.; Takemura, M.; Sun, W.; Onogi, K.; Wu, Y.; Seishima, M.; Mori, H.; Tamaya, T. Significant anti-proliferation of human endometrial cancer cells by combined treatment with a selective cox-2 inhibitor ns398 and specific mek inhibitor u0126. Int. J. Oncol. 2005, 26, 737-744.
151. Bank, A.; Yu, J.; Zhang, L. NSAIDs downregulate bcl-x(l) and dissociate bax and bcl-x(l) to induce apoptosis in colon cancer cells. Nutr. Cancer 2008, 60 (Suppl. 1), 98-103.
152. Lu, X.; Fairbairn, D.W.; Bradshaw, W.S.; O'Neill, K.L.; Ewert, D.L.; Simmons, D.L. Nsaid-induced apoptosis in rous sarcoma virus-transformed chicken embryo fibroblasts is dependent on v-src and c-myc and is inhibited by bcl-2. Prostaglandins 1997, 54, 549-568.
153. Raza, H.; John, A. Implications of altered glutathione metabolism in aspirin-induced oxidative stress and mitochondrial dysfunction in hepg2 cells. PLoS One 2012, 7, e36325.
154. Raza, H.; John, A.; Benedict, S. Acetylsalicylic acid-induced oxidative stress, cell cycle arrest, apoptosis and mitochondrial dysfunction in human hepatoma hepg2 cells. Eur. J. Pharmacol. 2011, 668, 15-24.
155. Raza, H.; John, A.; Howarth, F.C. Alterations in glutathione redox metabolism, oxidative stress, and mitochondrial function in the left ventricle of elderly zucker diabetic fatty rat heart. Int. J. Mol. Sci. 2012, 13, 16241-16254.
156. Rousar, T.; Parik, P.; Kucera, O.; Bartos, M.; Cervinkova, Z. Glutathione reductase is inhibited by acetaminophen-glutathione conjugate in vitro. Physiol. Res./Acad. Sci. Bohemoslov. 2010, 59, 225-232.
157. Sun, Y.; Rigas, B. The thioredoxin system mediates redox-induced cell death in human colon cancer cells: Implications for the mechanism of action of anticancer agents. Cancer Res. 2008, 68, 8269-8277.
158. Uwakwe, A.A.; Monanu, M.O. In vitro effects of aspirin and paracetamol on human erythrocyte glutathione-s-transferase activity. Glob. J. Med. Sci. 2004, 3, 33-36.
159. Duffy, C.P.; Elliott, C.J.; O'Connor, R.A.; Heenan, M.M.; Coyle, S.; Cleary, I.M.; Kavanagh, K.; Verhaegen, S.; O'Loughlin, C.M.; NicAmhlaoibh, R.; et al. Enhancement of chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of non-steroidal antiinflammatory drugs (NSAIDs). Eur. J. Cancer 1998, 34, 1250-1259.
160. Hurd, T.R.; Costa, N.J.; Dahm, C.C.; Beer, S.M.; Brown, S.E.; Filipovska, A.; Murphy, M.P. Glutathionylation of mitochondrial proteins. Antioxid. Redox Signal. 2005, 7, 999-1010.
161. Traverso, N.; Ricciarelli, R.; Nitti, M.; Marengo, B.; Furfaro, A.L.; Pronzato, M.A.; Marinari, U.M.; Domenicotti, C. Role of glutathione in cancer progression and chemoresistance. Oxidative Med. Cell. Longev. 2013, 2013, 972913.
162. Zhang, J.; Grek, C.; Ye, Z.W.; Manevich, Y.; Tew, K.D.; Townsend, D.M. Pleiotropic functions of glutathione s-transferase p. Adv. Cancer Res. 2014, 122, 143-175.
163. Singh, S. Cytoprotective and regulatory functions of glutathione s-transferases in cancer cell proliferation and cell death. Cancer Chemother. Pharmacol. 2014, 75, 1-15.
164. Beer, S.M.; Taylor, E.R.; Brown, S.E.; Dahm, C.C.; Costa, N.J.; Runswick, M.J.; Murphy, M.P. Glutaredoxin 2 catalyzes the reversible oxidation and glutathionylation of mitochondrial membrane thiol proteins: Implications for mitochondrial redox regulation and antioxidant defense. J. Biol. Chem. 2004, 279, 47939-47951.
165. Meredith, M.J.; Reed, D.J. Status of the mitochondrial pool of glutathione in the isolated hepatocyte. J. Biol. Chem. 1982, 257, 3747-3753.
166. Costa, N.J.; Dahm, C.C.; Hurrell, F.; Taylor, E.R.; Murphy, M.P. Interactions of mitochondrial thiols with nitric oxide. Antioxid. Redox Signal. 2003, 5, 291-305.
167. Griffith, O.W.; Meister, A. Origin and turnover of mitochondrial glutathione. Proc. Natl. Acad. Sci. USA 1985, 82, 4668-4672.
168. Reed, D.J. Glutathione: Toxicological implications. Annu. Rev. Pharmacol. Toxicol. 1990, 30, 603-631.
169. St-Pierre, J.; Buckingham, J.A.; Roebuck, S.J.; Brand, M.D. Topology of superoxide production from different sites in the mitochondrial electron transport chain. J. Biol. Chem. 2002, 277, 44784-44790.
170. Taylor, E.R.; Hurrell, F.; Shannon, R.J.; Lin, T.K.; Hirst, J.; Murphy, M.P. Reversible glutathionylation of complex i increases mitochondrial superoxide formation. J. Biol. Chem. 2003, 278, 19603-19610.
171. Mailloux, R.J.; Jin, X.; Willmore, W.G. Redox regulation of mitochondrial function with emphasis on cysteine oxidation reactions. Redox Biol. 2014, 2, 123-139.
172. Reid, A.B.; Kurten, R.C.; McCullough, S.S.; Brock, R.W.; Hinson, J.A. Mechanisms of acetaminophen-induced hepatotoxicity: Role of oxidative stress and mitochondrial permeability transition in freshly isolated mouse hepatocytes. J. Pharmacol. Exp. Ther. 2005, 312, 509-516.
173. Van Bladeren, P.J. Glutathione conjugation as a bioactivation reaction. Chem.-Biol. Interact. 2000, 129, 61-76.
174. Marchetti, M.; Resnick, L.; Gamliel, E.; Kesaraju, S.; Weissbach, H.; Binninger, D. Sulindac enhances the killing of cancer cells exposed to oxidative stress. PLoS One 2009, 4, e5804.
175. Al-Belooshi, T.; John, A.; Tariq, S.; Al-Otaiba, A.; Raza, H. Increased mitochondrial stress and modulation of mitochondrial respiratory enzyme activities in acetaminophen-induced toxicity in mouse macrophage cells. Food Chem. Toxicol. 2010, 48, 2624-2632.
176. Kwon, K.S.; Chae, H.J. Sodium salicylate inhibits expression of cox-2 through suppression of erk and subsequent nf-kappab activation in rat ventricular cardiomyocytes. Arch. Pharm. Res. 2003, 26, 545-553.
177. Carrett-Dias, M.; Votto, A.P.; Filgueira Dde, M.; Almeida, D.V.; Vallochi, A.L.; D'Oca, M.G.; Marins, L.F.; Trindade, G.S. Anti-mdr and antitumoral action of acetylsalicylic acid on leukaemic cells. Biosci. Rep. 2011, 31, 391-398.
178. Aithal, G.P.; Day, C.P. Nonsteroidal anti-inflammatory drug-induced hepatotoxicity. Clin. Liver Dis. 2007, 11, 563-575, vi-vii.
179. Gertz, M.; Fischer, F.; Leipelt, M.; Wolters, D.; Steegborn, C. Identification of peroxiredoxin 1 as a novel interaction partner for the lifespan regulator protein p66shc. Aging 2009, 1, 254-265.
180. Orsini, F.; Migliaccio, E.; Moroni, M.; Contursi, C.; Raker, V.A.; Piccini, D.; Martin-Padura, I.; Pelliccia, G.; Trinei, M.; Bono, M.; et al. The life span determinant p66shc localizes to mitochondria where it associates with mitochondrial heat shock protein 70 and regulates trans-membrane potential. J. Biol. Chem. 2004, 279, 25689-25695.
181. Lu, J.; Holmgren, A. The thioredoxin antioxidant system. Free Radic. Biol. Med. 2014, 66, 75-87.
182. Cunniff, B.; Snider, G.W.; Fredette, N.; Stumpff, J.; Hondal, R.J.; Heintz, N.H. Resolution of oxidative stress by thioredoxin reductase: Cysteine versus selenocysteine. Redox Biol. 2014, 2, 475-484.
183. Soethoudt, M.; Peskin, A.V.; Dickerhof, N.; Paton, L.N.; Pace, P.E.; Winterbourn, C.C. Interaction of adenanthin with glutathione and thiol enzymes: Selectivity for thioredoxin reductase and inhibition of peroxiredoxin recycling. Free Radic. Biol. Med. 2014, 77, 331-339.
184. Duan, D.; Zhang, B.; Yao, J.; Liu, Y.; Fang, J. Shikonin targets cytosolic thioredoxin reductase to induce ros-mediated apoptosis in human promyelocytic leukemia hl-60 cells. Free Radic. Biol. Med. 2014, 70, 182-193.
185. Duan, D.; Zhang, B.; Yao, J.; Liu, Y.; Sun, J.; Ge, C.; Peng, S.; Fang, J. Gambogic acid induces apoptosis in hepatocellular carcinoma smmc-7721 cells by targeting cytosolic thioredoxin reductase. Free Radic. Biol. Med. 2014, 69, 15-25.
186. Du, Y.; Zhang, H.; Zhang, X.; Lu, J.; Holmgren, A. Thioredoxin 1 is inactivated due to oxidation induced by peroxiredoxin under oxidative stress and reactivated by the glutaredoxin system. J. Biol. Chem. 2013, 288, 32241-32247.
187. Galimov, E.R. The role of p66shc in oxidative stress and apoptosis. Acta Nat. 2010, 2, 44-51.
188. Galimov, E.R.; Chernyak, B.V.; Sidorenko, A.S.; Tereshkova, A.V.; Chumakov, P.M. Prooxidant properties of p66shc are mediated by mitochondria in human cells. PLoS One 2014, 9, e86521.
189. Savino, C.; Pelicci, P.; Giorgio, M. The p66shc/mitochondrial permeability transition pore pathway determines neurodegeneration. Oxidative Med. Cell. Longev. 2013, 2013, 719407.
190. Giorgio, M.; Migliaccio, E.; Orsini, F.; Paolucci, D.; Moroni, M.; Contursi, C.; Pelliccia, G.; Luzi, L.; Minucci, S.; Marcaccio, M.; et al. Electron transfer between cytochrome c and p66shc generates reactive oxygen species that trigger mitochondrial apoptosis. Cell 2005, 122, 221-233.
191. Trinei, M.; Giorgio, M.; Cicalese, A.; Barozzi, S.; Ventura, A.; Migliaccio, E.; Milia, E.; Padura, I.M.; Raker, V.A.; Maccarana, M.; et al. A p53-p66shc signalling pathway controls intracellular redox status, levels of oxidation-damaged DNA and oxidative stress-induced apoptosis. Oncogene 2002, 21, 3872-3878.
192. Li, L.; Zhang, Y.G.; Chen, C.L. Anti-apoptotic role of peroxiredoxin iii in cervical cancer cells. FEBS Open Bio 2013, 3, 51-54.
193. Whitaker, H.C.; Patel, D.; Howat, W.J.; Warren, A.Y.; Kay, J.D.; Sangan, T.; Marioni, J.C.; Mitchell, J.; Aldridge, S.; Luxton, H.J.; et al. Peroxiredoxin-3 is overexpressed in prostate cancer and promotes cancer cell survival by protecting cells from oxidative stress. Br. J. Cancer 2013, 109, 983-993.
194. Szabo, I.; Zoratti, M. Mitochondrial channels: Ion fluxes and more. Physiol. Rev. 2014, 94, 519-608.
195. Leanza, L.; Zoratti, M.; Gulbins, E.; Szabo, I. Mitochondrial ion channels as oncological targets. Oncogene 2014, 33, 5569-5581.
196. Bonnet, S.; Archer, S.L.; Allalunis-Turner, J.; Haromy, A.; Beaulieu, C.; Thompson, R.; Lee, C.T.; Lopaschuk, G.D.; Puttagunta, L.; Bonnet, S.; et al. A mitochondria-k+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 2007, 11, 37-51.
197. Leanza, L.; Henry, B.; Sassi, N.; Zoratti, M.; Chandy, K.G.; Gulbins, E.; Szabo, I. Inhibitors of mitochondrial kv1.3 channels induce bax/bak-independent death of cancer cells. EMBO Mol. Med. 2012, 4, 577-593.
198. Schennach, R.; Obermeier, M.; Seemuller, F.; Jager, M.; Schmauss, M.; Laux, G.; Pfeiffer, H.; Naber, D.; Schmidt, L.G.; Gaebel, W.; et al. Evaluating depressive symptoms in schizophrenia: A psychometric comparison of the calgary depression scale for schizophrenia and the hamilton depression rating scale. Psychopathology 2012, 45, 276-285.
199. Archer, S.L.; Gomberg-Maitland, M.; Maitland, M.L.; Rich, S.; Garcia, J.G.; Weir, E.K. Mitochondrial metabolism, redox signaling, and fusion: A mitochondria-ros-hif-1alpha-kv1.5 o2-sensing pathway at the intersection of pulmonary hypertension and cancer. Am. J. Physiol. Heart Circ. Physiol. 2008, 294, H570-578.
200. Caouette, D.; Dongmo, C.; Berube, J.; Fournier, D.; Daleau, P. Hydrogen peroxide modulates the kv1.5 channel expressed in a mammalian cell line. Naunyn-Schmiedeberg's Arch. Pharmacol. 2003, 368, 479-486.
201. Platoshyn, O.; Brevnova, E.E.; Burg, E.D.; Yu, Y.; Remillard, C.V.; Yuan, J.X. Acute hypoxia selectively inhibits kcna5 channels in pulmonary artery smooth muscle cells. Am. J. Physiol. Cell Physiol. 2006, 290, C907-916.
202. Ye, H.; Ma, W.L.; Yang, M.L.; Liu, S.Y.; Wang, D.X. Effect of chronic cigarette smoking on large-conductance calcium-activated potassium channel and kv1.5 expression in bronchial smooth muscle cells of rats. Sheng li xue bao : [Acta Physiol. Sin.] 2004, 56, 573-578.
203. Szabo, I.; Bock, J.; Grassme, H.; Soddemann, M.; Wilker, B.; Lang, F.; Zoratti, M.; Gulbins, E. Mitochondrial potassium channel kv1.3 mediates bax-induced apoptosis in lymphocytes. Proc. Natl. Acad. Sci. USA 2008, 105, 14861-14866.
204. Szabo, I.; Leanza, L.; Gulbins, E.; Zoratti, M. Physiology of potassium channels in the inner membrane of mitochondria. Pflugers Archiv.: Eur. J. Physiol. 2012, 463, 231-246.
205. Szabo, I.; Soddemann, M.; Leanza, L.; Zoratti, M.; Gulbins, E. Single-point mutations of a lysine residue change function of bax and bcl-xl expressed in bax- and bak-less mouse embryonic fibroblasts: Novel insights into the molecular mechanisms of bax-induced apoptosis. Cell Death Differ. 2011, 18, 427-438.
206. Annis, M.G.; Soucie, E.L.; Dlugosz, P.J.; Cruz-Aguado, J.A.; Penn, L.Z.; Leber, B.; Andrews, D.W. Bax forms multispanning monomers that oligomerize to permeabilize membranes during apoptosis. EMBO J. 2005, 24, 2096-2103.
207. Liu, H.L.; Lin, J.C. A set of homology models of pore loop domain of six eukaryotic voltagegated potassium channels kv1.1-kv1.6. Proteins 2004, 55, 558-567.
208. Ruppersberg, J.P.; Stocker, M.; Pongs, O.; Heinemann, S.H.; Frank, R.; Koenen, M. Regulation of fast inactivation of cloned mammalian Ik(A) channels by cysteine oxidation. Nature 1991, 352, 711-714.
209. Pan, Y.; Weng, J.; Levin, E.J.; Zhou, M. Oxidation of nadph on kvbeta1 inhibits ball-and-chain type inactivation by restraining the chain. Proc. Natl. Acad. Sci. USA 2011, 108, 5885-5890.
210. Ochi, T. Inhibition of the activity of glutathione peroxidase by tertiary-butylhydroperoxide in cultured chinese hamster cells and the role of cellular glutathione in the recovery of the activity. Toxicology 1992, 71, 119-127.
211. Kushnareva, Y.E.; Sokolove, P.M. Prooxidants open both the mitochondrial permeability transition pore and a low-conductance channel in the inner mitochondrial membrane. Arch. Biochem. Biophys. 2000, 376, 377-388.
212. Byrne, A.M.; Lemasters, J.J.; Nieminen, A.L. Contribution of increased mitochondrial free ca2+ to the mitochondrial permeability transition induced by tert-butylhydroperoxide in rat hepatocytes. Hepatology 1999, 29, 1523-1531.
213. Bustamante, J.; Nutt, L.; Orrenius, S.; Gogvadze, V. Arsenic stimulates release of cytochrome c from isolated mitochondria via induction of mitochondrial permeability transition. Toxicol. Appl. Pharmacol. 2005, 207, 110-116.
214. Chernyak, B.V.; Bernardi, P. The mitochondrial permeability transition pore is modulated by oxidative agents through both pyridine nucleotides and glutathione at two separate sites. Eur. J. Biochem./FEBS 1996, 238, 623-630.
215. Connern, C.P.; Halestrap, A.P. Recruitment of mitochondrial cyclophilin to the mitochondrial inner membrane under conditions of oxidative stress that enhance the opening of a calciumsensitive non-specific channel. Biochem. J. 1994, 302 (Pt 2), 321-324.
216. Costantini, P.; Belzacq, A.S.; Vieira, H.L.; Larochette, N.; de Pablo, M.A.; Zamzami, N.; Susin, S.A.; Brenner, C.; Kroemer, G. Oxidation of a critical thiol residue of the adenine nucleotide translocator enforces bcl-2-independent permeability transition pore opening and apoptosis. Oncogene 2000, 19, 307-314.
217. Rettig, J.; Heinemann, S.H.; Wunder, F.; Lorra, C.; Parcej, D.N.; Dolly, J.O.; Pongs, O. Inactivation properties of voltage-gated k+ channels altered by presence of beta-subunit. Nature 1994, 369, 289-294.
218. Shin, J.H.; Lee, J.E.; Park, J.M.; Suh, C.K. T-butyl hydrogen peroxide increases the activities of the maxi-k channels of rat brain. Life Sci. 2000, 67, 2485-2491.
219. Martin, D.K.; Schyvens, C.G.; Wyse, K.R.; Bursill, J.A.; Owe-Young, R.A.; Macdonald, P.S.; Campbell, T.J. Role of non-steroidal anti-inflammatory drugs (NSAIDs) in modulating vascular smooth muscle cells by activating large-conductance potassium ion channels. In Patch Clamp Technique; InTech: Bratislava, Slovakia, 2012; pp. 283-300.
220. Bernardi, P. The mitochondrial permeability transition pore: A mystery solved? Front. Physiol. 2013, 4, 95.
221. Antoniel, M.; Giorgio, V.; Fogolari, F.; Glick, G.D.; Bernardi, P.; Lippe, G. The oligomycinsensitivity conferring protein of mitochondrial atp synthase: Emerging new roles in mitochondrial pathophysiology. Int. J. Mol. Sci. 2014, 15, 7513-7536.
222. Hattori, T.; Watanabe, K.; Uechi, Y.; Yoshioka, H.; Ohta, Y. Repetitive transient depolarizations of the inner mitochondrial membrane induced by proton pumping. Biophys. J. 2005, 88, 2340-2349.
223. Barsukova, A.; Komarov, A.; Hajnoczky, G.; Bernardi, P.; Bourdette, D.; Forte, M. Activation of the mitochondrial permeability transition pore modulates ca2+ responses to physiological stimuli in adult neurons. Eur. J. Neurosci. 2011, 33, 831-842.
224. Alavian, K.N.; Beutner, G.; Lazrove, E.; Sacchetti, S.; Park, H.A.; Licznerski, P.; Li, H.; Nabili, P.; Hockensmith, K.; Graham, M.; et al. An uncoupling channel within the c-subunit ring of the f1fo atp synthase is the mitochondrial permeability transition pore. Proc. Natl. Acad. Sci. USA 2014, 111, 10580-10585.
225. Alavian, K.N.; Dworetzky, S.I.; Bonanni, L.; Zhang, P.; Sacchetti, S.; Li, H.; Signore, A.P.; Smith, P.J.; Gribkoff, V.K.; Jonas, E.A. The mitochondrial complex v-associated largeconductance inner membrane current is regulated by cyclosporine and dexpramipexole. Mol. Pharmacol. 2014, 87, 1-8.
226. Giorgio, V.; von Stockum, S.; Antoniel, M.; Fabbro, A.; Fogolari, F.; Forte, M.; Glick, G.D.; Petronilli, V.; Zoratti, M.; Szabo, I.; et al. Dimers of mitochondrial atp synthase form the permeability transition pore. Proc. Natl. Acad. Sci. USA 2013, 110, 5887-5892.
227. Faccenda, D.; Campanella, M. Molecular regulation of the mitochondrial f(1)f(o)-atpsynthase: Physiological and pathological significance of the inhibitory factor 1 (if(1)). Int. J. Cell Biol. 2012, 2012, 367934.
228. Formentini, L.; Pereira, M.P.; Sanchez-Cenizo, L.; Santacatterina, F.; Lucas, J.J.; Navarro, C.; Martinez-Serrano, A.; Cuezva, J.M. In vivo inhibition of the mitochondrial h+-atp synthase in neurons promotes metabolic preconditioning. EMBO J. 2014, 33, 762-778.
229. Formentini, L.; Sanchez-Arago, M.; Sanchez-Cenizo, L.; Cuezva, J.M. The mitochondrial atpase inhibitory factor 1 triggers a ros-mediated retrograde prosurvival and proliferative response. Mol. Cell 2012, 45, 731-742.
230. Faccenda, D.; Tan, C.H.; Duchen, M.R.; Campanella, M. Mitochondrial if(1) preserves cristae structure to limit apoptotic cell death signaling. Cell Cycle 2013, 12, 2530-2532.
231. Faccenda, D.; Tan, C.H.; Seraphim, A.; Duchen, M.R.; Campanella, M. If1 limits the apoptotic-signalling cascade by preventing mitochondrial remodelling. Cell Death Differ. 2013, 20, 686-697.
232. Sanchez-Arago, M.; Formentini, L.; Garcia-Bermudez, J.; Cuezva, J.M. If1 reprograms energy metabolism and signals the oncogenic phenotype in cancer. Cell Cycle 2012, 11, 2963-2964.
233. Sanchez-Arago, M.; Formentini, L.; Martinez-Reyes, I.; Garcia-Bermudez, J.; Santacatterina, F.; Sanchez-Cenizo, L.; Willers, I.M.; Aldea, M.; Najera, L.; Juarranz, A.; et al. Expression, regulation and clinical relevance of the atpase inhibitory factor 1 in human cancers. Oncogenesis 2013, 2, e46.
234. Sanchez-Arago, M.; Formentini, L.; Cuezva, J.M. Mitochondria-mediated energy adaption in cancer: The h(+)-atp synthase-geared switch of metabolism in human tumors. Antioxid. Redox Signal. 2013, 19, 285-298.
235. Rasola, A.; Bernardi, P. The mitochondrial permeability transition pore and its adaptive responses in tumor cells. Cell Calcium 2014, 56, 437-445.
236. 2+ channels: The complex thought. Biochim. Biophys. Acta 2014, 1843, 2322-2333.
237. Nielsen, N.; Lindemann, O.; Schwab, A. Trp channels and stim/orai proteins: Sensors and effectors of cancer and stroma cell migration. Br. J. Pharmacol. 2014, 171, 5524-5540.
238. Nunez, L.; Valero, R.A.; Senovilla, L.; Sanz-Blasco, S.; Garcia-Sancho, J.; Villalobos, C. Cell proliferation depends on mitochondrial ca2+ uptake: Inhibition by salicylate. J. Physiol. 2006, 571, 57-73.
239. Munoz, E.; Valero, R.A.; Quintana, A.; Hoth, M.; Nunez, L.; Villalobos, C. Nonsteroidal anti-inflammatory drugs inhibit vascular smooth muscle cell proliferation by enabling the ca2+-dependent inactivation of calcium release-activated calcium/orai channels normally prevented by mitochondria. J. Biol. Chem. 2011, 286, 16186-16196.
240. Brueggemann, L.I.; Mani, B.K.; Mackie, A.R.; Cribbs, L.L.; Byron, K.L. Novel actions of nonsteroidal anti-inflammatory drugs on vascular ion channels: Accounting for cardiovascular side effects and identifying new therapeutic applications. Mol. Cell. Pharmacol. 2010, 2, 15-19.
241. Brueggemann, L.I.; Mackie, A.R.; Mani, B.K.; Cribbs, L.L.; Byron, K.L. Differential effects of selective cyclooxygenase-2 inhibitors on vascular smooth muscle ion channels may account for differences in cardiovascular risk profiles. Mol. Pharmacol. 2009, 76, 1053-1061.
242. Lim, M.S.; Lim, P.L.; Gupta, R.; Boelsterli, U.A. Critical role of free cytosolic calcium, but not uncoupling, in mitochondrial permeability transition and cell death induced by diclofenac oxidative metabolites in immortalized human hepatocytes. Toxicol. Appl. Pharmacol. 2006, 217, 322-331.
243. Poon, G.K.; Chen, Q.; Teffera, Y.; Ngui, J.S.; Griffin, P.R.; Braun, M.P.; Doss, G.A.; Freeden, C.; Stearns, R.A.; Evans, D.C.; et al. Bioactivation of diclofenac via benzoquinone imine intermediates-identification of urinary mercapturic acid derivatives in rats and humans. Drug Metab. Dispos.: Biol. Fate Chem. 2001, 29, 1608-1613.
244. Grillo, M.P.; Ma, J.; Teffera, Y.; Waldon, D.J. A novel bioactivation pathway for 2-[2-(2,6- dichlorophenyl)aminophenyl]ethanoic acid (diclofenac) initiated by cytochrome p450-mediated oxidative decarboxylation. Drug Metab. Dispos.: Biol. Fate Chem. 2008, 36, 1740-1744.
245. Hansson, M.J.; Mansson, R.; Morota, S.; Uchino, H.; Kallur, T.; Sumi, T.; Ishii, N.; Shimazu, M.; Keep, M.F.; Jegorov, A.; et al. Calcium-induced generation of reactive oxygen species in brain mitochondria is mediated by permeability transition. Free Radic. Biol. Med. 2008, 45, 284-294.
246. LoGuidice, A.; Ramirez-Alcantara, V.; Proli, A.; Gavillet, B.; Boelsterli, U.A. Pharmacologic targeting or genetic deletion of mitochondrial cyclophilin d protects from nsaid-induced small intestinal ulceration in mice. Toxicol. Sci.: Off. J. Soc. Toxicol. 2010, 118, 276-285.
247. Symersky, J.; Osowski, D.; Walters, D.E.; Mueller, D.M. Oligomycin frames a common drugbinding site in the atp synthase. Proc. Natl. Acad. Sci. USA 2012, 109, 13961-13965.
248. Bonora, M.; Bononi, A.; de Marchi, E.; Giorgi, C.; Lebiedzinska, M.; Marchi, S.; Patergnani, S.; Rimessi, A.; Suski, J.M.; Wojtala, A.; et al. Role of the c subunit of the fo atp synthase in mitochondrial permeability transition. Cell Cycle 2013, 12, 674-683.
249. Azarashvili, T.; Odinokova, I.; Bakunts, A.; Ternovsky, V.; Krestinina, O.; Tyynela, J.; Saris, N.E. Potential role of subunit c of f0f1-atpase and subunit c of storage body in the mitochondrial permeability transition. Effect of the phosphorylation status of subunit c on pore opening. Cell Calcium 2014, 55, 69-77.
250. Santamaria, G.; Martinez-Diez, M.; Fabregat, I.; Cuezva, J.M. Efficient execution of cell death in non-glycolytic cells requires the generation of ROS controlled by the activity of mitochondrial h+-atp synthase. Carcinogenesis 2006, 27, 925-935.
251. Johnson, K.M.; Chen, X.; Boitano, A.; Swenson, L.; Opipari, A.W., Jr.; Glick, G.D. Identification and validation of the mitochondrial f1f0-atpase as the molecular target of the immunomodulatory benzodiazepine bz-423. Chem. Biol. 2005, 12, 485-496.
252. Johnson, K.M.; Cleary, J.; Fierke, C.A.; Opipari, A.W., Jr.; Glick, G.D. Mechanistic basis for therapeutic targeting of the mitochondrial f1f0-atpase. ACS Chem. Biol. 2006, 1, 304-308.
253. Wondrak, G.T. Redox-directed cancer therapeutics: Molecular mechanisms and opportunities. Antioxid. Redox Signal. 2009, 11, 3013-3069.
254. Martinez-Reyes, I.; Cuezva, J.M. The h(+)-atp synthase: A gate to ros-mediated cell death or cell survival. Biochim. Biophys. Acta 2014, 1837, 1099-1112.
255. Alavian, K.N.; Li, H.; Collis, L.; Bonanni, L.; Zeng, L.; Sacchetti, S.; Lazrove, E.; Nabili, P.; Flaherty, B.; Graham, M.; et al. Bcl-xl regulates metabolic efficiency of neurons through interaction with the mitochondrial f1fo atp synthase. Nat. Cell Biol. 2011, 13, 1224-1233.
256. Chen, Y.B.; Aon, M.A.; Hsu, Y.T.; Soane, L.; Teng, X.; McCaffery, J.M.; Cheng, W.C.; Qi, B.; Li, H.; Alavian, K.N.; et al. Bcl-xl regulates mitochondrial energetics by stabilizing the inner membrane potential. J. Cell Biol. 2011, 195, 263-276.
257. Costantini, P.; Colonna, R.; Bernardi, P. Induction of the mitochondrial permeability transition by n-ethylmaleimide depends on secondary oxidation of critical thiol groups. Potentiation by copper-ortho-phenanthroline without dimerization of the adenine nucleotide translocase. Biochim. Biophys. Acta 1998, 1365, 385-392.
258. Zoratti, M.; Szabo, I. The mitochondrial permeability transition. Biochim. Biophys. Acta 1995, 1241, 139-176.
259. Ralph, S.J. Arsenic-based antineoplastic drugs and their mechanisms of action. Met.-Based Drugs 2008, 2008, 260146.
260. Petronilli, V.; Costantini, P.; Scorrano, L.; Colonna, R.; Passamonti, S.; Bernardi, P. The voltage sensor of the mitochondrial permeability transition pore is tuned by the oxidation-reduction state of vicinal thiols. Increase of the gating potential by oxidants and its reversal by reducing agents. J. Biol. Chem. 1994, 269, 16638-16642.
261. Costantini, P.; Chernyak, B.V.; Petronilli, V.; Bernardi, P. Modulation of the mitochondrial permeability transition pore by pyridine nucleotides and dithiol oxidation at two separate sites. J. Biol. Chem. 1996, 271, 6746-6751.
262. Skonberg, C.; Olsen, J.; Madsen, K.G.; Hansen, S.H.; Grillo, M.P. Metabolic activation of carboxylic acids. Expert Opin. Drug Metab. Toxicol. 2008, 4, 425-438.
263. 2+ channel (CRAC) by curcumin and caffeic acid phenethyl ester (CAPE) via electrophilic addition to a cysteine residue of orai1. Biochem. Biophys. Res. Commun. 2012, 428, 56-61.
264. Callister, M.E.; Pinhu, L.; Catley, M.C.; Westwell, A.D.; Newton, R.; Leaver, S.K.; Quinlan, G.J.; Evans, T.W.; Griffiths, M.J.; Burke-Gaffney, A. Pmx464, a thiol-reactive quinol and putative thioredoxin inhibitor, inhibits nf-kappab-dependent proinflammatory activation of alveolar epithelial cells. Br. J. Pharmacol. 2008, 155, 661-672.
265. Ahmad, R.; Raina, D.; Meyer, C.; Kufe, D. Triterpenoid cddo-methyl ester inhibits the janusactivated kinase-1 (jak1)-->signal transducer and activator of transcription-3 (stat3) pathway by direct inhibition of jak1 and stat3. Cancer Res. 2008, 68, 2920-2926.
266. Ahmad, R.; Raina, D.; Meyer, C.; Kharbanda, S.; Kufe, D. Triterpenoid cddo-me blocks the nf-kappab pathway by direct inhibition of ikkbeta on cys-179. J. Biol. Chem. 2006, 281, 35764-35769.
267. Kuang, S.; Qi, C.; Liu, J.; Sun, X.; Zhang, Q.; Sima, Z.; Liu, J.; Li, W.; Yu, Q. 2-methoxystypandrone inhibits signal transducer and activator of transcription 3 and nuclear factor-kappab signaling by inhibiting janus kinase 2 and ikappab kinase. Cancer Sci. 2014, 105, 473-480.
268. Lee, Y.; Shin, D.H.; Kim, J.H.; Hong, S.; Choi, D.; Kim, Y.J.; Kwak, M.K.; Jung, Y. Caffeic acid phenethyl ester-mediated nrf2 activation and ikappab kinase inhibition are involved in nfkappab inhibitory effect: Structural analysis for nfkappab inhibition. Eur. J. Pharmacol. 2010, 643, 21-28.
269. Jeon, K.I.; Jeong, J.Y.; Jue, D.M. Thiol-reactive metal compounds inhibit nf-kappa b activation by blocking i kappa b kinase. J. Immunol. 2000, 164, 5981-5989.
270. Kataoka, T. Chemical biology of inflammatory cytokine signaling. J. Antibiot. 2009, 62, 655-667.
271. Yin, M.J.; Yamamoto, Y.; Gaynor, R.B. The anti-inflammatory agents aspirin and salicylate inhibit the activity of i(kappa)b kinase-beta. Nature 1998, 396, 77-80.
272. Kudugunti, S.K.; Thorsheim, H.; Yousef, M.S.; Guan, L.; Moridani, M.Y. The metabolic bioactivation of caffeic acid phenethyl ester (cape) mediated by tyrosinase selectively inhibits glutathione s-transferase. Chem.-Biol. Interact. 2011, 192, 243-256.
273. Wardman, P. Bioreductive activation of quinones: Redox properties and thiol reactivity. Free Radic. Res. Commun. 1990, 8, 219-229.
274. Li, W.W.; Heinze, J.; Haehnel, W. Site-specific binding of quinones to proteins through thiol addition and addition-elimination reactions. J. Am. Chem. Soc. 2005, 127, 6140-6141.
275. Di Monte, D.; Bellomo, G.; Thor, H.; Nicotera, P.; Orrenius, S. Menadione-induced cytotoxicity is associated with protein thiol oxidation and alteration in intracellular ca2+ homeostasis. Arch. Biochem. Biophys. 1984, 235, 343-350.
276. Di Monte, D.; Ross, D.; Bellomo, G.; Eklow, L.; Orrenius, S. Alterations in intracellular thiol homeostasis during the metabolism of menadione by isolated rat hepatocytes. Arch. Biochem. Biophys. 1984, 235, 334-342.
277. Imaizumi, N.; Aniya, Y. The role of a membrane-bound glutathione transferase in the peroxynitrite-induced mitochondrial permeability transition pore: Formation of a disulfide-linked protein complex. Arch. Biochem. Biophys. 2011, 516, 160-172.
278. Aniya, Y.; Imaizumi, N. Mitochondrial glutathione transferases involving a new function for membrane permeability transition pore regulation. Drug Metab. Rev. 2011, 43, 292-299.
279. Shimoji, M.; Imaizumi, N.; Aniya, Y. Modulation of membrane-bound glutathione transferase activity by phospholipids including cardiolipin. Biol. Pharm. Bull. 2011, 34, 209-213.
280. Ulziikhishig, E.; Lee, K.K.; Hossain, Q.S.; Higa, Y.; Imaizumi, N.; Aniya, Y. Inhibition of mitochondrial membrane bound-glutathione transferase by mitochondrial permeability transition inhibitors including cyclosporin a. Life Sci. 2010, 86, 726-732.
281. McStay, G.P.; Clarke, S.J.; Halestrap, A.P. Role of critical thiol groups on the matrix surface of the adenine nucleotide translocase in the mechanism of the mitochondrial permeability transition pore. Biochem. J. 2002, 367, 541-548.
282. Pestana, C.R.; Silva, C.H.; Uyemura, S.A.; Santos, A.C.; Curti, C. Impact of adenosine nucleotide translocase (ant) proline isomerization on ca2+-induced cysteine relative mobility/mitochondrial permeability transition pore. J. Bioenerg. Biomembr. 2010, 42, 329-335.
283. 2+ binding to c-state of adenine nucleotide translocase (ant)-surrounding cardiolipins enhances (ant)-cys(56) relative mobility: A computational-based mitochondrial permeability transition study. Biochim. Biophys. Acta 2009, 1787, 176-182.
284. Halestrap, A.P. What is the mitochondrial permeability transition pore? J. Mol. Cell. Cardiol. 2009, 46, 821-831.
285. Suh, D.H.; Kim, M.K.; Kim, H.S.; Chung, H.H.; Song, Y.S. Mitochondrial permeability transition pore as a selective target for anti-cancer therapy. Front. Oncol. 2013, 3, 41.
286. American Cancer Society. Global Cancer Facts & Figures, 2nd. edition. Atlanta, GA, USA, 2011; pp. 1-57.
287. World Cancer Report. Stewart, B.W., Kleihues, P. Eds. IARC Press: Lyon, France, 2003.